Title:
BINDING AGENTS FOR USE IN THERAPY
Document Type and Number:
WIPO Patent Application WO/2018/050852
Kind Code:
A3
Abstract:
The present invention providesabinding agent capable of binding to the extracellular domain of CLPTM1 for use in the treatment or prevention of a condition which is responsive to, or benefits from, (i) immunosuppression, (ii) the reduction or reversal of one or more pro-inflammatory cytokines or the induction of an anti-inflammatory cytokine), (iii) an increase in insulin sensitivity, or (iv) therapy with GDF15 and/or TGF-βand/or IFNβ, wherein said binding agent has an EC 50 value of 1 μg/ml or less when determined by measuring binding to membrane-permeabilised O-876 cells expressing native CLPTM1 by flow cytometry, and wherein said binding agent is not a natural ligand for CLPTM.
Inventors:
BLOKZIJL OLOF ANDRIES (SE)
FREDRIKSSON JOHAN ERIK SIMON (SE)
FREDRIKSSON JOHAN ERIK SIMON (SE)
Application Number:
PCT/EP2017/073338
Publication Date:
January 10, 2019
Filing Date:
September 15, 2017
Export Citation:
Assignee:
GENAGON THERAPEUTICS AB (SE)
International Classes:
A61K39/395; C07K16/28
Domestic Patent References:
| WO2015197446A1 | 2015-12-30 | |||
| WO2004058805A2 | 2004-07-15 |
Other References:
ELISA REIMER: "Identification and characterization of proteins involved in proper functioning of UNC93B-Toll-like receptor complexes (dissertation)", 31 December 2014 (2014-12-31), pages 1 - 158, XP055421223, Retrieved from the Internet [retrieved on 20171102]
J. CORRE ET AL: "Concise Review: Growth Differentiation Factor 15 in Pathology: A Clinical Role?", STEM CELLS TRANSLATIONAL MEDICINE : SCTM, vol. 2, no. 12, 1 December 2013 (2013-12-01), Durham, pages 946 - 952, XP055330730, ISSN: 2157-6564, DOI: 10.5966/sctm.2013-0055
AIHARA KEN-ICHI ET AL: "Transforming Growth Factor-[beta]1 as a Common Target Molecule for Development of Cardiovascular Diseases, Renal Insufficiency and Metabolic Syndrome.", CARDIOLOGY RESEARCH AND PRACTICE, vol. 2011, 175381, 28 December 2010 (2010-12-28), XP002786559, ISSN: 2090-0597, DOI: 10.4061/2011/175381
RAMU ADELA ET AL: "GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective", JOURNAL OF DIABETES RESEARCH, vol. 12, no. 6, 490842, 1 January 2015 (2015-01-01), pages 1 - 14, XP055274535, ISSN: 2314-6745, DOI: 10.1155/2015/490842
J. CORRE ET AL: "Concise Review: Growth Differentiation Factor 15 in Pathology: A Clinical Role?", STEM CELLS TRANSLATIONAL MEDICINE : SCTM, vol. 2, no. 12, 1 December 2013 (2013-12-01), Durham, pages 946 - 952, XP055330730, ISSN: 2157-6564, DOI: 10.5966/sctm.2013-0055
AIHARA KEN-ICHI ET AL: "Transforming Growth Factor-[beta]1 as a Common Target Molecule for Development of Cardiovascular Diseases, Renal Insufficiency and Metabolic Syndrome.", CARDIOLOGY RESEARCH AND PRACTICE, vol. 2011, 175381, 28 December 2010 (2010-12-28), XP002786559, ISSN: 2090-0597, DOI: 10.4061/2011/175381
RAMU ADELA ET AL: "GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective", JOURNAL OF DIABETES RESEARCH, vol. 12, no. 6, 490842, 1 January 2015 (2015-01-01), pages 1 - 14, XP055274535, ISSN: 2314-6745, DOI: 10.1155/2015/490842
Attorney, Agent or Firm:
DZIEGLEWSKA, Hanna (GB)
Download PDF:
Previous Patent: TREATMENT OF NON-HODGKIN LYMPHOMA USING LILOTOMAB AND 177LU-LILOTOMAB SATETRAXETAN
Next Patent: A GAS CYLINDER MONITORING SYSTEM
Next Patent: A GAS CYLINDER MONITORING SYSTEM